Answers are grounded in this paper and cite their sources.
This review highlights peptide-based biomaterials improving radiotherapy by acting as radiosensitizers and radiopharmaceuticals.
Radiotherapy (RT) is a mainstay therapeutic strategy for cancer; however, increasing radiation damage to tumor tissues while reducing the side effects on healthy tissues remains a great challenge. To address this issue, the use of biomaterials has proven promising. Recently, attention has been paid to peptide‐based biomaterials as platforms for enhancing radiotherapeutic efficacy. This review explores peptide‐based biomaterial‐mediated tumor RT, including radiosensitizers and radiopharmaceuticals, with the aim of introducing emerging radiosensitive methods and RT strategies using radiopharmaceuticals. The advantages of peptide‐based biomaterials, including controllable synthesis, good biocompatibility, targeting functions, and self‐assembly performance, are introduced. These parameters must be considered in the rational design and optimization of peptide‐based RT strategies. Peptide‐based radiosensitizers are generally divided into three categories: peptides as direct radiosensitizers, peptides as carriers of radiosensitizers, and targeted‐peptide‐modified radiosensitizers. Peptide‐based radiopharmaceuticals are known as peptide‐radionuclide conjugates (PRCs) and are categorized according to their peptide targets. Details of PRCs used in clinical studies and US Food and Drug Administration‐approved PRCs are also presented. Finally, challenges in the clinical translation of peptide‐based biomaterials as RT tools are highlighted.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: